India Pharma Outlook Team | Wednesday, 18 November 2026
Ichnos Glenmark has taken an important step in advancing its experimental cancer drug ISB 2301 towards human clinical trials after submitting an Investigational New Drug application to the USFDA.
The submission brings Ichnos Glenmark Innovation (IGI), the biotechnology joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, closer to testing its next-generation cancer immunotherapy in patients with solid tumors.
The company plans to begin Phase 1 clinical trials in 2027, subject to regulatory clearance. The development also marks an expansion of IGI's oncology research beyond blood cancers into solid tumor treatments.
ISB 2301 represents a first-in-class pentaspecific molecule that combines multiple tumor-targeting and immune-activating functions within one candidate. Ichnos Glenmark developed the experimental drug to address tumor diversity and immune suppression, which create major challenges in treating solid cancers.
Key features of the candidate include:
“ISB 2301 is a super exciting asset, no one has ever tried to target both NK cells as well as activate T cells, right, along with these tumor antigens. However, from a deal perspective, we will wait until at least we get some clinical data in humans and get some proof of concept before we start looking at a potential partner,” said Glenn Saldanha, Chairman and MD, Glenmark Pharmaceuticals.
Also Read: Moving Indian Pharma from Volume to Value Through Innovation and Strategic Partnerships
The FDA IND submission brings ISB 2301 closer to its proposed first-in-human evaluation. Ichnos Glenmark plans to initiate Phase 1 trials in 2027 among patients with advanced solid tumors.
The clinical study will assess:
The development also complements IGI's broader oncology pipeline, particularly ISB 2001, its investigational trispecific antibody for multiple myeloma. IGI previously licensed ISB 2001 to AbbVie under an agreement worth up to USD 1.9 billion, including upfront and milestone-linked payments.
With ISB 2301, Ichnos Glenmark aims to extend its multispecific antibody research beyond blood cancers. Its progress into clinical trials could strengthen IGI's oncology portfolio and bring a new approach to experimental solid tumor treatments.